IMRX - Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors.
As of Jun 30, 2026: spot at $4.91, ATM IV 100.1%, max pain $5.00, net GEX $55.2K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $172.8M
- Beta
- 0.38
- 52-Week Range
- 2.9-10.08
- CEO
- Benjamin J. Zeskind
- Employees
- 54
- IPO Date
- Jul 30, 2021
- Exchange
- NASDAQ
What IMRX Looks Like to Options Traders Today
IV rank of 19.2% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($55.2K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.127) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The IMRX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked IMRX overview questions
- What is IMRX?
- IMRX is the ticker symbol for Immuneering Corporation, a listed security. Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. Listed on NASDAQ. IMRX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the IMRX options snapshot look like today?
- As of Jun 30, 2026, the IMRX options snapshot shows spot at $4.91, ATM IV 100.1%, IV rank 19.2%, max pain $5.00, net GEX $55.2K, expected move 28.70%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are IMRX's key statistics?
- Immuneering Corporation (IMRX) carries a market capitalization of $172.8M, beta of 0.38 relative to the broader market, 52-week range of 2.9-10.08. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does IMRX belong to?
- Immuneering Corporation operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare IMRX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the IMRX data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).